-56 patients (11 men, 45 women, median age 60) with 6 months of symptomatic thumb osteoarthritis treated at 2 orthopedic departments in Germany -Exclusion criteria included alcohol/drug abuse, intra-articular steroid within 3 months or hyaluronate injection within 6 months prior to study, joint effusion, inflammatory joint disease or infection -All had 3 weekly intra-articular injections, randomized to hyaluronate (n=28) or to triamcinolone suspension (n=28) -Blinded observers measured effectiveness at 3, 14, and 26 weeks after the first injection; pain VAS, heat/swelling/crepitations, lateral (key) pinch grip, pulp pinch grip, and range of motion were the main outcomes -In the short term, steroid relieved pain faster than hyaluronate up to week 14;
Authors' conclusions:
-Both hyaluronate and steroid injections effectively treat thumb OA -Steroid shows faster pain relief, but hyaluronate shows better long-term results -A placebo group was lacking, and data collection may have been biased because it was collected by orthopedists who delivered therapy Comments: -Several points of ambiguity and confusion seem to be present -The methods section states that outcomes were measured by masked observers, but the discussion section states that data was collected by the treating orthopedists -The "analysis of homogeneity" section does not deal with a statistical analysis of that name, but simply looks at baseline comparability of treatment groups -There is a statement that for joint function after 6 months, "moderate superiority of the SH group was found), but the proportions of improvement given (52% for the hyaluronate group and 42.3% for the steroid group) can be calculated to have very wide confidence intervals, with no difference between groups -Authors appear to be stretching criteria for significance; lateral pinch pain shows a "slight superiority" of the hyaluronate group at 6 months, but the p value is 0.1966 -Pain scores were expressed as median rather than as mean values "for reduction of outliers' impact," but since VAS is on a scale of 0-10, it is not clear that outliers are relevant, as they are on scales with no imposed ceiling -Method of randomization is not given, nor can concealment be assumed Assessment: Inadequate for superiority of either injection either to placebo or to one another at any follow-up time
